US-based company that produces monoclonal antibodies (mAbs) primarily for use in preclinical in vivo research applications Bio X Cell announced on Monday that it has named Christopher Conway as its new chief executive officer.

The company says that Conway, a seasoned business executive, has more than 20 years' consistent track record of exceeding goals, developing talent and change transformation across a variety of industry verticals: aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. He has exceeded growth goals in various roles at AMRI, Johnson & Johnson, and Dynabil Industries. He has also worked as president of Research and Development (R&D) at Curia.

Conway said, 'Bio X Cell's tremendous brand reputation throughout the global research community, especially within academia and government, is a testament to the care and attention Klaus and team have brought to the business since its founding in 1997. The opportunity to build on that strong foundation, continue to expand upon Bio X Cell's high quality, extensive product offering, and extend its reach within the commercial sector, both organically and through strategic acquisitions, are what attracted me to the CEO role.'